



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

## POLICY ON MATERIALITY OF RELATED PARTY TRANSACTIONS AND ON DEALING WITH RELATED PARTY TRANSACTIONS [Adopted on 27.08.2024]

### 1. INTRODUCTION

Sub-regulation 1 of Regulation 23 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (effective December 1, 2015) and in terms of Section 188 of the Companies Act, 2013 is intended to ensure proper approval, disclosure and reporting requirements of transactions between the Company and its Related Parties and requires listed entity to formulate a policy on materiality of related party transactions and on dealing with related party transactions including clear threshold limits duly approved by the Board of Directors (the “Board”) at least once in every three years and updated accordingly.

The Board of Paramesu Biotech Limited (the “Company”), has adopted the following policy and procedures with regard to Related Party Transactions on 27-08-2024 as defined below. The Audit Committee may from time to time review and recommend amendments to this policy to the Board. The Board may amend this policy from time to time.

This policy is to regulate transactions between the Company and its Related Parties based on the applicable laws and regulations applicable on the Company.

### 2. POLICY OBJECTIVE

The objective of this policy is to ensure proper approval and reporting of transactions between the Company and its Related Parties. This policy intends to bring uniform practices relating to Related Party Transactions covering the process, methodology, arm’s length pricing, disclosures and compliance with the provisions of the Companies Act, 2013 and rules framed thereunder, and the SEBI LODR Regulations.

### 3. DEFINITIONS

3.1 “Audit Committee” or “Committee” means the committee constituted by the Board of Directors of the Company, from time to time, under the provisions of Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Section 177 of the Companies Act, 2013.

3.2 “Arm’s Length Basis” means the terms will be treated as on ‘Arm’s Length Basis’ if the commercial and key terms are comparable and are not materially different with similar transactions with non-related parties considering all the aspects of the transactions such as quality, realizations, other terms of the contract, etc. In case of contracts with related parties for specified period / quantity / services, it is possible that the terms of one off comparable transaction with an unrelated party are at variance, during the validity of contract with related party. In case the Company is not doing similar transactions with any other non-related party, terms for similar transactions between other non-related parties of similar standing can be considered to establish ‘arm’s length’.

“Board of Directors” or “Board” means the Board of Directors of Paramesu Biotech Limited, as constituted from time to time.



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

- 3.3 **“Company”** means Paramesu Biotech Limited
- 3.4 **“Key Managerial Personnel”** shall have the meaning ascribed to the term under Section 2(51) the Companies Act, 2013 and shall mean:
- (i) The Chief Executive Officer or the Managing Director or the manager;
  - (ii) The Whole-time Director;
  - (iii) The Chief Financial Officer; and
  - (iv) Such other officer as may be prescribed under the Companies Act, 2013.

- 3.5 **“Material Related Party Transaction”** means a transaction with a Related Party if the transaction / transactions to be entered into individually or taken together with previous transactions during a financial year exceeds 10% percent of the annual consolidated revenue from operations of the Company as per the last audited financial statements of the Company.

Notwithstanding the above, a transaction involving payments made to a related party with respect to brand usage or royalty shall be considered material if the transaction(s) to be entered into individually or taken together with previous transactions during a financial year, exceed five percent of the annual consolidated turnover of the Company as per the last audited financial statements of the Company.

- 3.6 **“Policy”** means this policy on Related Party Transactions as amended from time to time
- 3.7 **“Related Party”**, in relation to the Company, shall refer to an entity which is:
- (i) A related party under Section 2(76) of the Companies Act, 2013; or
  - (ii) A related party under the applicable accounting standards.

The parties specified in Section 2(76) of the Companies Act, 2013 are as under:

- (i) a director or his relative;
  - (ii) a key managerial personnel or his relative;
  - (iii) a firm, in which a director, manager or his relative is a partner;
  - (iv) a private company in which a director or manager or his relative is a member or director;
  - (v) a public company in which a director or manager is a director and holds along with his relatives, more than two per cent of its paid- up share capital;
  - (vi) corporate whose Board of Directors, managing director or manager is accustomed to act in accordance with the advice, directions or instructions of a director or manager;
  - (vii) Any person on whose advice, directions or instructions a director or manager is accustomed to act.
-



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

Provided that nothing in sub-clauses (VI) and (vii) shall apply to the advice, directions or instructions given in a professional capacity;

- (viii) Any company which is –
  - (A) A holding, subsidiary or an associate company of the company; or
  - (B) A subsidiary of a holding company to which it is also a subsidiary;
  - (c) An investing Company or the venture of the Company
- (viii) a director (other than an Independent Director) or key managerial personnel of the holding company or his relative with reference to the Company
- (x) Such other person as may be prescribed.

3.8 **“Related Party Transaction”** means a transfer of resources, services or obligations between the Company and a Related Party and any transaction as defined under regulation 2 (zc) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regardless of whether a price is charged and a “transaction” with a related party shall be construed to include a single transaction or a group of transactions in a contract.

3.9 **“Relative”** means relative as defined under the Companies Act, 2013 and, with reference to any person, means anyone who is related to another, if –

- i. They are members of a Hindu undivided family;
- ii. They are husband and wife; or
- iii. Father (including step-father);
- iv. Mother (including step-mother);
- v. Son (including step-son);
- vi. Son’s wife;
- vii. Daughter;
- viii. Daughter’s husband;
- ix. Brother (including step-brother);
- x. Sister (including step-sister);
- xi. One person is related to the other in such manner as may be prescribed under the Companies Act, 2013.

## 4. POLICY

### 4.1. Identification of Related Parties:

The Company Secretary, based on the declarations provided by the Directors and Key Managerial Personnel and also based on the corporate structure shall prepare a list of all persons who shall be considered as related parties with reference to the Company.

### 4.2. Identification of potential Related Party Transactions:



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

Each Director and Key Managerial Personnel is responsible for providing notice to the Board or Audit Committee of any potential Related Party Transaction involving him or her or his or her Relative, including any additional information about the transaction that the Board/Audit Committee may reasonably request. The Audit Committee would determine whether the transaction does, in fact, constitute a Related Party Transaction requiring compliance with this policy.

Each Director shall disclose of his interest or concern (MBP-1) to the Company and this disclosure shall be placed before the Board of Directors at their first meeting held in the financial year. Any further change in the list of relatives or change in interest shall be intimated by the Directors from time to time, as may be required.

Directors are also required to provide the information regarding their engagement with other entity during the financial year which may be regarded as related party according to this policy.

The Company shall receive such notice of any potential Related Party Transaction well in advance so that the Audit Committee / Board has adequate time to obtain and review information about the proposed transaction.

#### **4.3. Restrictions related to Related Party Transactions**

All Related Party Transactions shall require prior approval of Audit Committee. Provided that only those members of the audit committee, who are independent directors, shall approve related party transactions. However, the Audit Committee may grant omnibus approval for Related Party Transactions proposed to be entered into by the company subject to the following conditions:

- a. The Audit Committee shall lay down the criteria for granting the omnibus approval in line with this policy and such approval shall be applicable in respect of transactions which are repetitive in nature.
- b. The Audit Committee shall satisfy itself on the need for such omnibus approval and that such approval is in the interest of the company;
- c. Such omnibus approval shall specify:
  - i. the name/s of the related party, nature of transaction, period of transaction, maximum amount of transaction that can be entered into,
  - ii. the indicative base price / current contracted price and the formula for variation in the price if any; and
  - iii. such other conditions as the Audit Committee may deem fit;

Provided that where the need for Related Party Transaction cannot be foreseen and aforesaid details are not available, Audit Committee may grant omnibus approval for such transactions subject to their value not exceeding Rs. 1,00,00,000 (Rupees One Crore Only) per transaction.



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

- d. Audit Committee shall review, at least on a quarterly basis, the details of related party transactions entered into by the company pursuant to each of the omnibus approval given.
- e. Such omnibus approvals shall be valid for a period not exceeding one year and shall require fresh approvals after the expiry of one year.

Further, all Material Related Party Transactions shall require approval of the shareholders through ordinary resolution and no related party shall vote to approve such resolutions whether the entity is a related party to the particular transaction or not

Nothing contained in this Paragraph 4.3 shall apply to transactions entered into between the Company and its wholly owned subsidiary/ies whose accounts are consolidated with the Company and such consolidated accounts are placed before the shareholders of the Company at the general meeting for approval (such transaction are hereinafter referred to as "Exempted Transactions").

The provisions contained in this Paragraph 4.3 shall be applicable to all prospective transactions.

For the purpose of this Paragraph 4.3, all entities falling under the definition of related parties shall not vote to approve the relevant transaction irrespective of whether the entity is a party to the particular transaction or not.

The Company shall submit within 30 days from the date of publication of its standalone and consolidated financial results for the half year, disclosures of related party transactions on a consolidated basis, in the format specified in the relevant accounting standards for annual results to the stock exchanges and publish the same on its website.

#### **4.4. Review and Approval of Related Party Transactions by Audit Committee**

All Related Party Transactions, including Material Related Party Transaction but excluding Exempted Transactions, will be put to the Audit Committee for its review and prior approval in a meeting or by way of circular resolution. Any member of the Committee who has a potential interest in any Related Party Transaction will rescue himself or herself and abstain from discussion and voting on the approval of the Related Party Transaction.

To review a Related Party Transaction, the Committee will be provided with all relevant material information of the Related Party Transaction, including the terms of the transaction, the business purpose of the transaction, the benefits/ loss to the Company, and any other relevant matters.

In determining whether to approve a Related Party Transaction, the Committee may consider all such factors/ or may call such information/ or seek external advice/ opinion as it may consider appropriate in its sole judgment.

If the Committee determines that a Related Party Transaction should be brought before the Board, or if the Board in any case elects to review any such matter or it is mandatory under any law for Board to approve



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

the Related Party Transaction, then the considerations set forth above shall apply to the Board's review and approval of the matter, with such modification as may be necessary.

All the transactions including Material Modifications which are identified by the Audit Committee as related party transactions should be pre-approved by the Audit Committee before entering into such transaction. The Audit committee to consider the following factors while deliberating the related party transactions for its approval: -

- Name of party and details explaining nature of relationship;
- Duration of the contract and particulars of the contract and arrangement;
- Nature of transaction and material terms thereof including the value, if any;
- Whether at arm's length or not;
- Business rationale for entering into such transaction;
- Any other information relevant or important for the Board to take a decision on the proposed transaction.

Any member of the Committee who has a potential interest in any Related Party Transaction will rescue himself and abstain from discussion and voting on the approval of the Related Party Transaction, if the Committee determines that the related party transaction is:

- A Material related party transaction; or
- Transactions are not in the ordinary course of business or not at the arm's length price, the Audit Committee shall place the matter before the Board for obtaining its approval.

In determining whether to approve a Related Party Transaction, the Committee may consider the following factors, among others, to the extent relevant to the Related Party Transaction:

- Whether the terms of the Related Party Transaction are fair and on arm's length basis to the Company and would apply on the same basis if the transaction did not involve a Related Party;
- Whether there are any compelling business reasons / rationale for the Company to enter into the Related Party Transaction and the nature of alternative transactions, if any;
- Whether the Related Party Transaction would affect the Independence of an Independent Director;
- Whether the proposed transaction includes any potential reputational risk issues that may arise as a result of or in connection with the proposed transaction;
- Whether the Company was notified about the Related Party Transaction before its commencement and if not, why pre-approval was not sought and whether subsequent ratification is allowed and would be detrimental to the Company; and
- Whether the Related Party Transaction would present an improper conflict of interest for any Director or Key Managerial Personnel of the Company, taking into account the size of the transaction, the overall financial position of the Director, Executive Officer or other Related Party, the direct or indirect nature of the Director's, Key Managerial Personnel's or other Related Party's interest in the transaction and the ongoing nature of any proposed relationship and any other factors the Board/Committee deems relevant.
- Audit committee may grant omnibus approval for related party transactions proposed to be entered into by the company subject to the following conditions, namely:



# PARAMESU BIOTECH LIMITED

(formerly known as PARAMESU BIOTECH PRIVATE LIMITED)

Registered Office: RS No. 972, 3rd KM Gopalapuram Road,  
Devarapalli, West Godavari District - 534313, Andhra Pradesh.

---

- viii. the audit committee shall lay down the criteria for granting the omnibus approval in line with the policy on related party transactions of the company and such approval shall be applicable in respect of transactions which are repetitive in nature;

## **5. POST FACTO CONSIDERATION OF RELATED PARTY TRANSACTIONS**

In the event the Company becomes aware of a Related Party Transaction with a Related Party that has not been approved under this Policy, the matter shall be reviewed by the Committee. The Committee shall consider all of the relevant facts and circumstances regarding the Related Party Transaction, and shall evaluate all options available to the Company, including ratification, revision or termination of the Related Party Transaction.

In connection with any review of a Related Party Transaction, the Committee has authority to modify or waive any procedural requirements of this Policy.

This Policy will be communicated to all operational employees and other concerned persons of the Company.

## **6. REVIEW AND UPDATION OF THE POLICY**

In case of any subsequent changes in the provisions of the Companies Act, SEBI LODR Regulations or any other regulations, which makes any of the provisions in the Policy inconsistent with the Regulations, the provisions of the Regulations would prevail over the Policy and the provisions in the Policy would be modified in due course to make it consistent with the Regulations. The Board shall review this policy at least once in every three years and if necessary shall update the same on the recommendation of the Committee.

## **7. DISCLOSURES**

This Policy will be disclosed on the Company's website [www.paramesubiotech.com](http://www.paramesubiotech.com) and a web link to the same would be disclosed in the Annual Report of the Company.